Eunice L Kwak

Title: Eunice L Kwak: Innovator in Cancer Treatment

Introduction

Eunice L Kwak is a notable inventor based in Marlborough, MA (US), recognized for her contributions to cancer treatment methodologies. With a total of two patents, her work focuses on addressing challenges in treating gefitinib and erlotinib resistant cancers.

Latest Patents

Eunice L Kwak's latest patents include a method for treating gefitinib resistant cancer. This invention outlines a process where individuals with cancer are monitored for progression following treatment with gefitinib and/or erlotinib. If cancer progression is observed, indicating resistance to these treatments, the subject is administered a pharmaceutical composition that includes an irreversible epidermal growth factor receptor (EGFR) inhibitor. Preferred embodiments of this invention feature inhibitors such as EKB-569, HKI-272, and HKI-357.

Career Highlights

Throughout her career, Eunice has worked with prominent organizations, including The General Hospital Corporation and Wyeth. Her experience in these institutions has significantly contributed to her expertise in cancer research and treatment.

Collaborations

Eunice has collaborated with esteemed colleagues, including Daniel Arie Haber and Daphne Winifred Bell, enhancing her research and development efforts in the field of oncology.

Conclusion

Eunice L Kwak's innovative approaches to cancer treatment exemplify her dedication to improving patient outcomes. Her patents and collaborations reflect her significant impact on the medical field, particularly in addressing drug resistance in cancer therapies.